Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

BACKGROUND: Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial. METHODS: The aim of this retrospective multicenter study wa...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Transl Med
मुख्य लेखकों: Cortellini, Alessio, Vitale, Maria G., De Galitiis, Federica, Di Pietro, Francesca R., Berardi, Rossana, Torniai, Mariangela, De Tursi, Michele, Grassadonia, Antonino, Di Marino, Pietro, Santini, Daniele, Zeppola, Tea, Anesi, Cecilia, Gelibter, Alain, Occhipinti, Mario Alberto, Botticelli, Andrea, Marchetti, Paolo, Rastelli, Francesca, Pergolesi, Federica, Tudini, Marianna, Silva, Rosa Rita, Mallardo, Domenico, Vanella, Vito, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2019
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857130/
https://ncbi.nlm.nih.gov/pubmed/31730009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-02132-x
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन